 The China National Medical Products Administration NMPA granted conditional approval for BeiGene Ltd NASDAQ: BGNE - EUSA Pharmas UK Qarziba dinutuximab beta in high-risk neuroblastoma patients. The approval comes for patients aged 12 months and above who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and stem cell transplantation. 